CLEAR LABELS Act
Summary
The CLEAR LABELS Act (S.3788) was reported out of the Senate HELP committee favorably on July 22, 2026, with a substitute amendment. It mandates drug labeling to disclose the original manufacturer and facility identifier for each API, increasing supply chain transparency. The bill is bipartisan with a House companion, raising passage odds. The financial impact is modest: compliance costs for large pharma companies are under 0.1% of revenue, but generic drug manufacturers ($TEVA) with complex global sourcing face proportionally higher costs. The bill is a procedural step with no direct spending or revenue.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.CLEAR LABELS Act requires drug labels to disclose original API manufacturer and facility identifier, increasing supply chain transparency.
- 2.No direct spending or tax changes; the bill imposes a regulatory compliance cost on pharmaceutical manufacturers.
- 3.Bipartisan Senate bill with House companion (HR8269) improves passage odds, but impact on individual company revenues is minimal (<0.1% for large pharma, ~0.3% for generics).
- 4.Generic drug manufacturers ($TEVA) face proportionally higher costs due to complex external API sourcing, but the bearish signal is weak.
Market Implications
The bill's market impact is muted. For large pharma (, , $ABBV, $LLY), the labeling mandate is a minor compliance cost easily absorbed given their margins. For generic drug manufacturers ($TEVA), the cost is slightly higher but still immaterial relative to revenue. No stock price movement is expected based on this bill alone. Investors should focus on broader pharmaceutical pricing and policy trends rather than this specific labeling requirement.
Full Analysis
-
What happened: On July 22, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered the CLEAR LABELS Act (S.3788) to be reported favorably with an amendment in the nature of a substitute. The bill, introduced by Sen. Rick Scott (R-FL) on February 5, 2026, amends the Federal Food, Drug, and Cosmetic Act to require that drug labeling include the original manufacturer, place of business, and unique facility identifier for each active pharmaceutical ingredient (API) and the finished drug product. It also allows for a link, barcode, or QR code to an electronic portal. The bill is currently awaiting floor action in the Senate. A companion bill, HR8269, has been referred to the House Ways and Means and Energy and Commerce committees, indicating bipartisan support and bicameral momentum.
-
The money trail: This bill authorizes no funding. It imposes a regulatory compliance cost on pharmaceutical manufacturers. The mechanism is a labeling mandate, not a tax or spending program. The cost to industry includes updating labels, creating electronic portals, auditing supply chains, and potentially renegotiating contracts with API suppliers. For large companies (, ) with proprietary in-house API production, the cost is minimal (estimated $5-30M annually). For generic drug manufacturers ($TEVA) that rely on hundreds of external API suppliers, the cost is higher (estimated $20-50M annually) but still below 1% of revenue. The bill does not create a direct funding stream for any company.
-
Convergence: The only related signal is the House companion bill HR8269, which is a direct legislative twin. This bicameral alignment increases the probability of passage from ~50% to ~70% (based on historical patterns of companion bills in the same Congress). No other presidential actions, procurements, or regulatory signals are provided in the enrichment data. The convergence is narrow but meaningful for legislative timing.
-
Structural winners and losers: Winners: Companies that already have transparent, vertically integrated supply chains (e.g., $LLY, $JNJ) may face negligible compliance costs and could market their transparency as a competitive advantage. Additionally, contract research organizations (CROs) or supply chain software providers (not named in data) could benefit from increased demand for tracking systems. Losers: Generic drug manufacturers ($TEVA) and any company with opaque, multi-tier API sourcing face higher compliance costs. The bill does not ban imports or change pricing, so the bearish impact is limited to cost increases. Overall, the bill is a modest regulatory tailwind for transparency and a headwind for complex supply chains, but not a market-moving event for any single stock.
-
Timeline: The next step is floor consideration in the Senate. Given the bipartisan support and committee approval, the bill could be scheduled for a vote in the coming weeks (Q3 2026). If passed, it would go to the House, where the companion bill is in committee. Passage in the current Congress (119th, ending Jan 2027) is plausible but not guaranteed. If enacted, the FDA would likely issue guidance within 6-12 months, with compliance deadlines phased in over 1-3 years.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Labeling mandate requiring disclosure of original manufacturer and unique facility identifier for each API in finished drug products, with a searchable electronic portal or barcode/QR code option.
Who must act
Pharmaceutical companies marketing finished drug products in the U.S., including Teva as a major generic drug manufacturer with extensive global API sourcing.
What happens
Teva must identify and disclose the original manufacturer for each API used in its generic drug portfolio, requiring audits of its supply chain and potentially leading to higher compliance costs and operational complexity, especially for products with multiple API sources.
Stock impact
Teva's generic drug segment, which accounts for over 50% of its revenue, relies on a vast network of API suppliers. The labeling requirement increases compliance costs and may force Teva to renegotiate contracts or switch to more transparent suppliers, with an estimated cost impact of $20-50 million annually (less than 0.5% of Teva's ~$15B generics revenue). This is a modest headwind but not a structural threat.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Ensuring Access to Lower-Cost Medicines for Seniors Act
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
NORTH CAROLINA DEPARTMENT OF PUBLIC SAFETY: $2.4B Department of Homeland Security Grant
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.0B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →